Our vision is to restore hope and health for patients diagnosed with untreatable cancers. There have been great advances in cancer therapeutics, but there’s still a lot of progress to be made. At Tegmine, we’ve developed a platform which employs cutting-edge mass spectrometry and CRISPR cell engineering to discover and develop higher-specificity antibody-based therapeutics. Our platform focuses on identifying proteins with tumor-specific modifications that drive disease progression and severity. By targeting proteins in their tumor-promoting state, we are developing high-precision antibodies for the next generation of anti-cancer therapeutics.